 Clinical-stage biopharmaceutical firm Synaptogenix NASDAQ: SNPX demonstrated the harsh pitfalls associated with innovative medicine. Following the disclosure of disappointing results for its Phase 2 study involving the treatment of advanced Alzheimers disease, SNPX stock dropped 70 on Friday morning, extending losses to around 74 in the late afternoon. 